GALT
GALECTIN THERAPEUTICS INC
Key Financials
Operating Income
$-20085000
↑ 52.7%
Net Income
$-30836000
↑ 34.5%
EPS (Diluted)
$-0.48
↑ 36.8%
Cash & Equivalents
$17.7M
↑ 17.2%
Total Liabilities
$145.7M
↑ 20.9%
Shareholders' Equity
$-127918000.00
↓ 22.1%
Total Assets
$19.5M
↑ 11.6%
Operating Cash Flow
$-23875000.00
↑ 42.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| SCHEDULE 13D/A | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 4 | 7/16/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 4 | 6/30/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 144 | 6/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GALT |
| Company Name | GALECTIN THERAPEUTICS INC |
| CIK | 1133416 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 678-620-3186 |